Moderator of 1 Session
Presenter of 1 Presentation
COMBINATION OF PLASMA AMYLOID AND BRIEF COGNITIVE ASSESSMENT IN IDENTIFYING PRODROMAL ALZHEIMER'S DISEASE
Abstract
Aims
Brief assessments of cognition have been used widely to identify individuals at risk for Alzheimer's diseasee (AD) dementia. Recent improvements in the accuracy of plasma amyliod biomarkers will allow determination of amyloid status to accompny case-finding cognitive assessments in the clinic. Thus cognitive impairment and abnormally high amyloid level (AB+) could identify prodromal AD [2]. We computed accuracy with which information from plasma amyloid measure could improve the ability of the Cogstate Brief Battery (CBB) to identify prodromal AD (mild cognitive impairment (MCI AB+) in older adults.
Methods
195 adults from the Australian Imaging Biomarker & Lifestyle (AIBL) with detailed clinical and amyloid PET data (80 cognitively unimpaired (CU) AB-, 60 CUAB+, 22 Mild cognitive impairment (MCI)AB- and 33 prodromal AD adults). Plasma samples were analyzed at Koichi Tanaka Mass Spectrometry Research Laboratory (Shimadzu corporation) . Plasma Aβ status was abnormal when composite score was ≥ 0.376 and Aβ- is plasma Aβ composite scores were < 0.376. Abnormal performance on the CBB was classified </=1SD learning or working memory score.
Results
CBB performance was abnromal in 17% CUAB-, 25%CUAB+, 55%MCIAB- and 85%ProdromalAD. Plasma AB was abnormal in 23% CUAB-, 82%CUAB+, 23%MCIAB- and 82%ProdromalAD. The combined criterion of abnormal plasma AB and CBB performance identified 80% of the prodromal AD group.
Conclusions
Combination of a plasma AB and the CBB provided a high sensitivity to prodromal AD, and therefore may provide a useful combination in clinical practice